The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Bousquet, J (Author) Other; Jutel, M (Author) Other; Pfaar, O (Author) Other; Fonseca, J (Author) FMUP; Agache, I (Author) Other; Czarlewski, W (Author) Other; Bachert, C (Author) Other; Bergmann, KC (Author) Other; Cruz, AA (Author) Other; Klimek, L (Author) Other; Kvedariene, V (Author) Other; Larenas Linnemann, DE (Author) Other; Papadopoulos, NG (Author) Other; Patella, V (Author) Other; Regateiro, FS (Author) Other; Scichilone, N (Author) Other; Shamji, MH (Author) Other; Sheikh, A (Author) Other; Valovirta, E (Author) Other; Ventura, MT (Author) Other; Zuberbier, T (Author) Other

Journal

Title: Journal of Allergy and Clinical Immunology: In Practice

Vol. 9

Pages: 1805-1812

ISSN: 2213-2198

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 16 Citations

Scopus - 14 Citations

Other information

Authenticus ID: P-00T-WDX

DOI: 10.1016/j.jaip.2021.02.035

Abstract (EN): Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. (C) 2021 American Academy of Allergy, Asthma & Immunology

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8